Evidence Summary
- Evidence Level
- Preliminary
- Mechanism
- Enrollment: Estimated, Sponsor Type: Industry, Unknown / General
- Safety
- Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
- Dosing
- See linked studies/trials for reported doses and durations; typical protocols vary widely.
CCR5 antagonist studied for persistent immune activation (often + statin). 300mg BID; LFT monitoring. Very early/experimental for these conditions.
Clinical Trials
1 trial(s) registered
| NCT ID | Title | Phase | Status |
|---|---|---|---|
| NCT06974084 | A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the | Phase 2 | Not yet recruiting |
Key Studies / References
- See linked studies